{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Atrial fibrillation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Febrile neutropenia (possibly related)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pneumonia (resulted in death)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Respiratory failure (resulted in death)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Adverse events were coded using the Medical Dictionary for Regulatory Activities, Version 11.0.","groups":[{"description":"Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles","id":"OG000","title":"Pemetrexed"}],"paramType":"NUMBER","populationDescription":"Patients who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"baseline, up to 18 weeks","title":"Discontinuations Due to Adverse Events","type":"SECONDARY","unitOfMeasure":"participants"}